| Patient | Higuchi Ichiyō |
|---|---|
| Date of birth | 1872-05-02 |
| Identifiers | MRN HR-NI029-SYN-TD; SSN (made up) 000-29-5108 |
| Document date | 2026-11-01 |
| Author | Aiko Lindgren-Tanaka, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health center. Concerns: She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosis; She supports her household by writing and cannot afford to stop working or to pay for many tests; She is afraid of passing the illness to the people she lives with and of what neighbors and editors will think. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Isoniazid 100 mg tablets, two tablets (200 mg) daily | 200 mg once daily, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Rifampin (rifampicin) 150 mg capsules, three capsules (450 mg) daily | 450 mg once daily on an empty stomach, observed by video each day through the public health center's directly observed treatment program, for 26 weeks | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily, observed by video each day through the public health center's directly observed treatment program, for the eight-week intensive phase | Oral route | 1896-04-17 to 1896-06-11 | completed | S |
| Ethambutol 100 mg tablets, six tablets (600 mg) daily | 600 mg once daily, observed by video each day through the public health center's directly observed treatment program, until susceptibility results return | Oral route | 1896-04-17 to 1896-05-22 | stopped | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 1896-04-17 to 1896-10-15 | completed | S |
| Nitrofurantoin monohydrate/macrocrystals 100 mg oral capsule, one capsule twice daily with food for five days | One capsule twice daily with food for five days | Oral route | 1896-07-20 to 1896-07-24 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest X-ray, two views: patchy opacities in the apical and posterior segments of the right upper lobe with small nodules; no cavity, effusion or hilar enlargement | 1896-04-14 to 1896-04-14 | completed | S |
| Chest X-ray, two views, at the end of treatment: right upper lobe opacities cleared, leaving a few linear scars; kept as the baseline for any future comparison | 1896-10-20 to 1896-10-20 | completed | S |
| Cervical cytology (Papanicolaou test), first screening | 1896-08-24 to 1896-08-24 | completed | S |
| Advance care planning conversation, about 16 minutes | 1896-08-24 to 1896-08-24 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1896-08-24 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 1896-08-24 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 1896-08-24 | Human papillomavirus 9-valent vaccine, dose 1 of 3 | completed | S |
| 1896-10-20 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 1896-10-20 | Human papillomavirus 9-valent vaccine, dose 2 of 3 | completed | S |
| 1896-10-20 | Influenza vaccine, inactivated, trivalent, preservative-free | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
No historical medical events are recorded.
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| father | Died of illness in 1889; cause not recorded in the cited source | D (CLM-0004) |
| Concern | Status | Evidence |
|---|---|---|
| She has coughed for weeks, sweats at night and has lost weight, and fears it is tuberculosis | active | S |
| She supports her household by writing and cannot afford to stop working or to pay for many tests | active | S |
| She is afraid of passing the illness to the people she lives with and of what neighbors and editors will think | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13.2 on 1896-10-20; Leukocytes [#/volume] in Blood by Automated count 8.6 on 1896-04-14; Platelets [#/volume] in Blood by Automated count 452 on 1896-04-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 on 1896-10-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 1896-10-20; Bilirubin.total [Mass/volume] in Serum or Plasma 0.5 on 1896-06-12; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 74 on 1896-04-14; Albumin [Mass/volume] in Serum or Plasma 4.2 on 1896-10-20; Creatinine [Mass/volume] in Serum or Plasma 0.56 on 1896-04-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1891)/1.73 sq M 131 on 1896-04-14; Glucose [Mass/volume] in Serum or Plasma 82 on 1896-04-14; Hemoglobin A1c/Hemoglobin.total in Blood 5.1 on 1896-04-14; Visual acuity uncorrected Right eye by ETDRS eye chart 85 on 1896-06-12; Visual acuity uncorrected Left eye by ETDRS eye chart 85 on 1896-06-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1896-10-20; Total score [AUDIT-C] 0 on 1896-08-24; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1896-08-24; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 4 on 1896-08-24 [S]
Strengths and supports: Supports and strengths she names: her writing, her readers and editors, and the poetry she studied when young [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about seven weeks with evening fevers, night sweats, poor appetite and weight loss of about 4 kg (about 10 percent) in a woman of 23; chest X-ray with patchy right upper lobe opacities and no cavity; suspected pulmonary tuberculosis; airborne precautions and three sputum specimens for acid-fast smear, nucleic acid amplification and culture | resolved | confirmed | R05.3 | S — Synthetic presenting problem at intake, superseded by the diagnosis at the second visit; its timing echoes her documented decline from early 1896 (D). |
| Pulmonary tuberculosis of the right upper lobe, sputum smear-negative, confirmed by Xpert MTB/RIF Ultra (Mycobacterium tuberculosis detected, low; rifampin resistance not detected) | resolved | confirmed | A15.0 | S — Synthetic modern coding of her documented tuberculosis; all bacteriology and imaging are synthetic. |
| Moderate protein-calorie malnutrition: BMI 17.6, about 10 percent weight loss in two months, and albumin 3.3 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutrition diagnosis at intake, anchored to her documented poverty. |
| Low and irregular income from writing, with a household to support; costs of care are a barrier | active | confirmed | Z59.6 | S — Synthetic social need anchored to her documented poverty and household responsibilities. |
| Acute uncomplicated cystitis, treated with nitrofurantoin rather than a fluoroquinolone during tuberculosis treatment; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent illness; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1896-04-14 | Hemoglobin [Mass/volume] in Blood | 11.4 | g/dL | 12-15.5 g/dL | Low | S |
| 1896-04-14 | Leukocytes [#/volume] in Blood by Automated count | 8.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1896-04-14 | Platelets [#/volume] in Blood by Automated count | 452 | 10*3/uL | 150-400 10*3/uL | High | S |
| 1896-04-14 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 12 | U/L | 7-35 U/L | Normal | S |
| 1896-04-14 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 10-35 U/L | Normal | S |
| 1896-04-14 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1896-04-14 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 74 | U/L | 35-104 U/L | Normal | S |
| 1896-04-14 | Albumin [Mass/volume] in Serum or Plasma | 3.3 | g/dL | 3.5-5 g/dL | Low | S |
| 1896-04-14 | Creatinine [Mass/volume] in Serum or Plasma | 0.56 | mg/dL | 0.5-1 mg/dL | Normal | S |
| 1896-04-14 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1891)/1.73 sq M | 131 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1896-04-14 | Glucose [Mass/volume] in Serum or Plasma | 82 | mg/dL | 70-99 mg/dL | Normal | S |
| 1896-04-14 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.1 | % | Below 5.7% is normal; 6.5% or more is diabetes | Normal | S |
| 1896-04-14 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 1896-04-14 | Visual acuity uncorrected Left eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 1896-04-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 1896-04-14 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 1896-05-01 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 1896-05-01 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-35 U/L | Normal | S |
| 1896-05-01 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1896-05-01 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 1896-05-01 | Visual acuity uncorrected Left eye by ETDRS eye chart | 84 | {letters} | >=80 | Normal | S |
| 1896-06-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
| 1896-06-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 25 | U/L | 10-35 U/L | Normal | S |
| 1896-06-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 1896-06-12 | Albumin [Mass/volume] in Serum or Plasma | 3.8 | g/dL | 3.5-5 g/dL | Normal | S |
| 1896-06-12 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 1896-06-12 | Visual acuity uncorrected Right eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 1896-06-12 | Visual acuity uncorrected Left eye by ETDRS eye chart | 85 | {letters} | >=80 | Normal | S |
| 1896-06-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1896-10-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 1896-10-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 10-35 U/L | Normal | S |
| 1896-10-20 | Albumin [Mass/volume] in Serum or Plasma | 4.2 | g/dL | 3.5-5 g/dL | Normal | S |
| 1896-10-20 | Hemoglobin [Mass/volume] in Blood | 13.2 | g/dL | 12-15.5 g/dL | Normal | S |
| 1896-10-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1896-08-24 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1896-08-24 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S | ||
| 1896-08-24 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1896-04-14 | Body height | 148 | cm | S |
| 1896-04-14 | Body weight | 38.5 | kg | S |
| 1896-04-14 | Body mass index (BMI) [Ratio] | 17.6 | kg/m2 | S |
| 1896-04-14 | Systolic blood pressure | 98 | mm[Hg] | S |
| 1896-04-14 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 1896-04-14 | Heart rate | 104 | /min | S |
| 1896-04-14 | Respiratory rate | 20 | /min | S |
| 1896-04-14 | Body temperature | 37.8 | Cel | S |
| 1896-04-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1896-04-17 | Body height | 148 | cm | S |
| 1896-04-17 | Body weight | 38.4 | kg | S |
| 1896-04-17 | Body mass index (BMI) [Ratio] | 17.5 | kg/m2 | S |
| 1896-04-17 | Systolic blood pressure | 96 | mm[Hg] | S |
| 1896-04-17 | Diastolic blood pressure | 60 | mm[Hg] | S |
| 1896-04-17 | Heart rate | 100 | /min | S |
| 1896-04-17 | Respiratory rate | 20 | /min | S |
| 1896-04-17 | Body temperature | 37.6 | Cel | S |
| 1896-04-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1896-05-01 | Body height | 148 | cm | S |
| 1896-05-01 | Body weight | 39.2 | kg | S |
| 1896-05-01 | Body mass index (BMI) [Ratio] | 17.9 | kg/m2 | S |
| 1896-05-01 | Systolic blood pressure | 100 | mm[Hg] | S |
| 1896-05-01 | Diastolic blood pressure | 62 | mm[Hg] | S |
| 1896-05-01 | Heart rate | 90 | /min | S |
| 1896-05-01 | Respiratory rate | 18 | /min | S |
| 1896-05-01 | Body temperature | 37.1 | Cel | S |
| 1896-05-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1896-06-12 | Body height | 148 | cm | S |
| 1896-06-12 | Body weight | 41 | kg | S |
| 1896-06-12 | Body mass index (BMI) [Ratio] | 18.7 | kg/m2 | S |
| 1896-06-12 | Systolic blood pressure | 102 | mm[Hg] | S |
| 1896-06-12 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1896-06-12 | Heart rate | 80 | /min | S |
| 1896-06-12 | Respiratory rate | 16 | /min | S |
| 1896-06-12 | Body temperature | 36.8 | Cel | S |
| 1896-06-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1896-10-20 | Body height | 148 | cm | S |
| 1896-10-20 | Body weight | 44 | kg | S |
| 1896-10-20 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1896-10-20 | Systolic blood pressure | 106 | mm[Hg] | S |
| 1896-10-20 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1896-10-20 | Heart rate | 72 | /min | S |
| 1896-10-20 | Respiratory rate | 14 | /min | S |
| 1896-10-20 | Body temperature | 36.5 | Cel | S |
| 1896-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1896-07-20 | Body height | 148 | cm | S |
| 1896-07-20 | Body weight | 42 | kg | S |
| 1896-07-20 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 1896-07-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1896-07-20 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1896-07-20 | Heart rate | 84 | /min | S |
| 1896-07-20 | Respiratory rate | 16 | /min | S |
| 1896-07-20 | Body temperature | 37 | Cel | S |
| 1896-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1896-08-24 | Body height | 148 | cm | S |
| 1896-08-24 | Body weight | 42.6 | kg | S |
| 1896-08-24 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 1896-08-24 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1896-08-24 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 1896-08-24 | Heart rate | 76 | /min | S |
| 1896-08-24 | Respiratory rate | 14 | /min | S |
| 1896-08-24 | Body temperature | 36.6 | Cel | S |
| 1896-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1896-04-14 | New patient visit for seven weeks of cough, fevers, night sweats and weight loss: chest X-ray, sputum specimens, blood tests, airborne precautions, and a report of suspected tuberculosis to the public health center | finished | S |
| 1896-04-17 | Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the standard six-month regimen | finished | S |
| 1896-05-01 | Two-week review on treatment: culture result, liver tests, vision, and release from precautions | finished | S |
| 1896-06-12 | End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase | finished | S |
| 1896-10-20 | End-of-treatment review after 182 doses | finished | S |
| 1896-07-20 | Same-day sick visit for acute cystitis during tuberculosis treatment | finished | S |
| 1896-08-24 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Diagnosis and safety: chest X-ray; three sputum specimens at least eight hours apart, one early in the morning, for acid-fast smear, Xpert MTB/RIF Ultra, liquid and solid culture and drug susceptibility testing; HIV, hepatitis B and hepatitis C tests and a pregnancy test; blood count, liver and kidney tests, glucose and hemoglobin A1c; visual acuity and color vision before ethambutol | completed | GL-ATS-TBDX-2017, GL-ATS-TB-2016, GL-WHO-TB-2022 | S |
| Infectious diseases consultation at the results visit to confirm the diagnosis, choose between the six-month and four-month regimens, set the doses for her weight, and plan monitoring and infection control | completed | GL-ATS-TB-2016, GL-ATS-TB-2025, GL-CDC-4MO-2022 | S |
| Infection control and public health: airborne precautions in the clinic; at home, no visitors, a surgical mask in shared rooms, windows open, and sleeping in her own room until the public health center confirms she is no longer infectious; report of suspected tuberculosis to the public health center the same day and notification at once on diagnosis; a contact investigation of her household and other close contacts led by the public health center | completed | GL-MHLW-TB-NOTIFY, GL-CDC-CONTACT-2005, GL-ATS-TB-2016 | S |
| Nutrition, income and writing: two dietitian visits in the first month, three meals and two energy-dense snacks a day with two oral nutrition supplement drinks, and weight at every visit; a medical social worker to apply for public funding of tuberculosis treatment and to review other help with costs; a paced writing plan of short sessions in daylight with rest; PHQ-9 at intake, at two months and at the end of treatment | completed | GL-ASPEN-MALN-2012, GL-JP-TB-FUNDING, GL-USPSTF-DEP-2023 | S |
| Treatment: isoniazid 200 mg, rifampin 450 mg, pyrazinamide 1000 mg and ethambutol 600 mg daily for eight weeks, then isoniazid and rifampin daily for eighteen weeks, with pyridoxine 50 mg, by daily video-observed therapy with the public health center; ethambutol stopped once the isolate is susceptible to isoniazid and rifampin; liver tests at two weeks and monthly in the intensive phase because of her low weight and albumin; visual acuity and color vision monthly while on ethambutol; sputum smear and culture at two weeks and two months; chest X-ray at the end of treatment | completed | GL-ATS-TB-2016, GL-ATS-TB-2025, GL-WHO-TB-2022, GL-ATS-HEPATOTOX-2006 | S |
| Acute cystitis: nitrofurantoin 100 mg twice daily for five days with urine culture; no fluoroquinolone, because these drugs are kept for drug-resistant tuberculosis and can blur the picture of tuberculosis; continue every tuberculosis dose; plenty of fluids; return for fever, flank pain, vomiting or symptoms that are not better in two days | completed | GL-IDSA-UTI-2010, GL-ATS-TB-2016 | S |
| Prevention: cervical cytology now and every three years; Tdap; hepatitis B vaccine in two doses and HPV vaccine in three doses; influenza vaccine in the autumn; folic acid 0.4 mg daily advised; contraception counseling that rifampin makes hormonal pills, patches, rings and implants unreliable, with a copper IUD, injectable progestin or condoms as reliable choices if she needs contraception during treatment | completed | GL-USPSTF-CERV-2018, GL-CDC-IMZ-2026, GL-CDC-SPR-2024, GL-USPSTF-FOLIC-2023 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Complete 182 daily doses within about six and a half months by video-observed therapy | 1896-10-20 | completed | All 182 doses completed in 26 weeks: 56 in the intensive phase and 126 in the continuation phase, none missed | S |
| Sputum culture negative at two months | 1896-10-20 | completed | The cultures taken at two weeks and at two months both showed no growth after six weeks | S |
| Weight at least 44 kg (BMI about 20) by the end of treatment | 1896-10-20 | completed | 44.0 kg at the end of treatment, from 38.5 kg at intake | S |
| Keep writing on a paced schedule without losing income during treatment | 1896-10-20 | completed | Public funding covered most treatment costs; she kept writing about two hours a day and finished new work | S |
| No drug-induced liver injury or loss of vision during treatment | 1896-10-20 | completed | Liver tests normal throughout; visual acuity unchanged | S |